Filing Flows › Supernus Pharmaceuticals (SUPN) › Net product sales revenue
Supernus Pharmaceuticals (SUPN) Net product sales revenue by quarter
Supernus Pharmaceuticals' Net product sales revenue was $179M in Q3 2026 (third quarter 2026), +7% from Q2 2026. Over the last 7 quarters it ranged from $142M (Q1 2025) to $179M (Q3 2026).
| Quarter | Net product sales revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $179M | +7% | +6% |
| Q2 2026 | $166M | +11% | +5% |
| Q1 2026 | $150M | -5% | +6% |
| Q4 2025 | $158M | -6% | — |
| Q3 2025 | $168M | +7% | — |
| Q2 2025 | $158M | +11% | — |
| Q1 2025 | $142M | — | — |
Q3 2026 at a glance
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Supernus Pharmaceuticals' Net product sales revenue?
Supernus Pharmaceuticals' Net product sales revenue was $179M in Q3 2026 (third quarter 2026), +7% from Q2 2026.
How has Supernus Pharmaceuticals' Net product sales revenue changed?
Over the last 7 quarters it ranged from $142M (Q1 2025) to $179M (Q3 2026).
Q3 2026 results → · How Supernus Pharmaceuticals makes money →